NF1 and melanoma: Several clinical trials have demonstrated the benefits of MEK inhibitors (e.g., trametinib (Robert et al., 2019), cobimetinib (Gutzmer et al., 2020), mirdametinib (Weiss et al., 2021) and selumetinib (Gross et al., 2020) in melanoma and NF1.